Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial

American Journal of Transplantation

Volumn 13, Issue 5, 2013, Pages 1203-1216

  Eisen, H J ^a   Kobashigawa, J ^b   Starling, R C ^c   Pauly, D F ^d   Kfoury, A ^e   Ross, H ^f   Wang, S S ^g   Cantin, B ^h   Van Bakel, A ⁱ   Ewald, G ^j   Hirt, S ^k   Lehmkuhl, H ^l   Keogh, A ^m   Rinaldi, M ⁿ   Potena, L ^o   Zuckermann, A ^p   Dong, G ^q   Cornu Artis, C ^q   Lopez, P ^q  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e INTERMOUNTAIN MEDICAL CENTER   (United States)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h LAVAL UNIVERSITY   (Canada)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^l DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^m ST VINCENT S HOSPITAL   (Australia)

ⁿ SGiovanni Battista di Torino   (Italy)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p UNIVERSITY OF VIENNA   (Austria)

^q NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Cardiac allograft vasculopathy; cyclosporine; everolimus; heart transplantation; mycophenolate mofetil; randomized

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPNEA; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSOMNIA; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEOPLASM; NEUTROPENIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; WOUND HEALING;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASIA; AUSTRALIA; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYOCARDIUM; NORTH AMERICA; PROSPECTIVE STUDIES; SIROLIMUS; SOUTH AMERICA; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84876930437     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12181     Document Type: Article

References (27)

1. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
2. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
3. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
4. Eisen H,. Long-term cardiovascular risk in transplantation: Insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3): iii9-13.
5. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507-515.
6. Note for guidance on good clinical practice (CPMP/ICH/135/95). London: European Agency for the Evaluation of Medicinal Products, July 2002. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500002874.pdf. Accessed February 24, 2012.
7. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/ 30publications/10policies/b3/index.html. Accessed February 24, 2012.
8. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100-108.
9. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-593.
10. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
11. OPTN/SRTR Annual Report (1999-2008). Available at: http://www.srtr.org/ annual-reports/2010/112a-dh.htm. Accessed April 14, 2012.
12. Fuchs U, Zittermann A, Schulz U, Gummert JF,. Efficacy and safety of low-dose everolimus as maintenance immunosuppression in cardiac transplant recipients. J Transplant 2012; 2012: 976921.
13. Schnetzler B, Leger P, Völp A, Dorent R, Pavie A, Gandjbakhch I,. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int 2002; 15: 317-325.
14. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352: 2705-2713.
15. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
16. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR,. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: 632-639.
17. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
18. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult heart transplant report, 2008. J Heart Lung Transplant 2008; 27: 943-956.
19. Prada-Delgado O, Estévez-Loureiro R, Paniagua-Martín MJ, Lõpez-Sainz A, Crespo-Leiro MG,. Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature. J Heart Lung Transplant 2012; 31: 332-333.
20. Tedesco Silva H Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-1413.
21. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant 2012; 12: 3008-3020.
22. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD,. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986; 8: 332-337.
23. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21: 460-465.
24. Lehmkuhl H, Arizon J, Viganò M, et al. Everolimus with reduced-exposure cyclosporine versus MMF with standard-exposure cyclosporine in de novo heart transplant reciepients. Transplantation 2009; 88: 115-122.
25. Viganò M, Dengler T, Mattei MF, et al. RAD A2411 Study Investigators. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study. Transpl Infect Dis 2010; 12: 23-30.
26. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453-2462.
27. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82: 398-405.